Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Emend, Fosaprepitant Dimeglumine, Focinvez, Navitrux. Every FDA application for this active ingredient: 4 branded and 19 generic.
As of Nov 15, 2026, FDA lists 23 applications for Fosaprepitant Dimeglumine (sold as Emend, Fosaprepitant Dimeglumine, Focinvez and others), first approved Jan 25, 2008, with 4 new uses approved and 1 published complete response letter.
First approved: Jan 25, 2008
Applications: 23
New uses approved: 4
Complete response letters: 1
Medicare spending, 2025: $16.3M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
FOCINVEZ
Part B
$13.5M
New
6,684
Emend
Part B
$1.5M
-32%
18,001
Fosaprepitant Dimeglumine
Part D
$609K
+17%
931
Fosaprepitant Dimeglumine
Part B
$567K
+106%
1,032
Focinvez
Part D
$60K
New
22
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
EMEND 125 MG POWDER PACKET: $327.38 per unitBrand · +0% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Fresenius Kabi USA
Mylan Labs Ltd
Apotex
Lupin
Baxter Hlthcare Corp
Accord Hlthcare
Eugia Pharma